Erin Wiltchik, MD
Pulmonary Disease · la Jolla, CANPI 1518498757
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,384 of the $20,550 with a category attached, or 60.3%. Sanofi accounts for 77.4% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $8,949, more than ten times the $23 reported in 2019. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $209.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$16K
- Medical Device Business Services, Inc.$1K
- Noah Medical Corporation$1K
- Astellas Pharma US Inc$350
- Pulmonx Corporation$271
- Johnson & Johnson$269
- plus $1K from 16 others
What the payments were for
- Consulting fees$12,38460%
- Travel & lodging$3,27216%
- Food & beverage$4,40821%
- Education$4862%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 38 | $15,911 |
| Medical Device Business Services, Inc. | 5 | $1,364 |
| Noah Medical Corporation | 8 | $1,089 |
| Astellas Pharma US Inc | 4 | $350 |
| Pulmonx Corporation | 2 | $271 |
| Johnson & Johnson | 2 | $269 |
| Boehringer Ingelheim | 6 | $155 |
| Inari Medical, Inc. | 2 | $152 |
| AstraZeneca | 8 | $144 |
| Sanofi-aventis U.S. LLC | 2 | $136 |
| Intuitive Surgical | 3 | $134 |
| Abiomed | 1 | $116 |
| Regeneron Healthcare Solutions, Inc. | 3 | $104 |
| Grifols USA, LLC | 3 | $91 |
| Actelion Pharmaceuticals US, Inc. | 2 | $63 |
| GSK | 2 | $46 |
| Insmed, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| United Therapeutics Corporation | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Electromed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,550 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in la Jolla
- Timothy Fernandesla Jolla$129K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.